Within the ongoing globalisation process, many national markets and industrial branches are in different phases of the transition from local to global economic structures (Bryan, L.; Fraser, J.; Oppenheim, J. Rall, W., 2000, pp. 71-95). As a result of this development organisations in the different industries are increasingly concentrating (Brühl, V., 2003, pp. 274-278).
Among other industries, also the pharmaceutical industry is highly influenced by the above mentioned trend, reflected by the increasing number of mergers and acquisitions (M&A’s) in the pharmaceutical industry, which is illustrated in the following figure.
Figure 1:
The present assignment is going to evaluate the reasons and consequences of M&A’s within the pharmaceutical industry by using the sanofi-aventis merger as an example. First of all, the recent history of sanofi-aventis is briefly described. The third part will describe the reasons and consequences of mergers and acquisitions in the pharmaceutical industry by describing the challenges the pharmaceutical branch is confronted with and the respective motives of and results from M&A activities. Finally, the major findings are summarised and conclusions will be derived.
2. History of sanofi-aventis
Following the company homepage of sanofi-aventis (20071), the year 1999 has been very im-portant because of two reasons.
First of all, Sanofi took over the Synthelabo Holding GmbH and changed its company name to Sanofi-Synthelabo. Furthermore, Hoechst merged with Rhône-Poulenc, a French chemical and pharmaceutical organisation in order to form the new company Aventis, with its legal seat in Strassbourgh (...)
Table of Contents
1. Introduction
2. History of sanofi-aventis
3. M&A’s in the Pharmaceutical Industry
3.1. Reasons for M&A’s in the Pharmaceutical Industry
3.2. Motives of Merging Organisations
3.2.1. Synergy Effects
3.2.2. Focus on Core Competences
3.2.3. Market Power
3.2.4. Management Motives
3.3. Consequences of M&A’s in the Pharmaceutical Industry
4. Conclusions
Objectives and Topics
This assignment evaluates the reasons and consequences of mergers and acquisitions in the global pharmaceutical industry, using the sanofi-aventis merger as a central case study to understand the drivers of industry concentration and the impact of such activities on corporate strategy and market dynamics.
- Drivers of consolidation in the pharmaceutical sector
- Strategic motives for mergers (synergies, core competences, market power)
- Consequences of large-scale M&A activities for companies and employment
- Challenges regarding research, development, and innovation potential
- The impact of global health care reforms and generic competition
Excerpt from the Book
3.2.3. Market Power
Maybe the most important reason for mergers is to strive for market power. By merging with, or the acquisition of a competitor, organisations aim for reducing the stress of competition and to get advantages in price competition. If an organisation achieves a monopoly situation, competition can completely be avoided and increased market prices can be enforced (Budzinski, Kerber, 2003, pp. 52-53). Furthermore, a monopolist can try to raise market entry barriers. In order to delimitate the danger of a monopolistic situation, merger control or antitrust agencies have to approve mergers, especially so-called mega-mergers where already strong and dominating competitors in an oligopolistic market try to merger (Motta, 2007, pp. 36-38).
Due to the 55 billion Euro merger of Sanofi-Synthelabo and Aventis to sanofi-aventis, the new organisation achieved a place within the top flight of international pharmaceutical companies (Bohne, 2004, p.11).
Summary of Chapters
1. Introduction: This chapter introduces the ongoing globalisation trend and the resulting concentration process within the pharmaceutical industry, setting the framework for the sanofi-aventis case study.
2. History of sanofi-aventis: This section details the corporate evolution of sanofi-aventis, highlighting the key mergers in 1999 and 2004 that led to the formation of the current group.
3. M&A’s in the Pharmaceutical Industry: This chapter provides a comprehensive analysis of the reasons, strategic motives (including synergy, core competence focus, and market power), and the socio-economic consequences of mergers in the pharmaceutical sector.
4. Conclusions: The final chapter summarizes the industry crisis, noting that despite high merger activity, the expected gains in innovation have not fully materialized and further consolidation is anticipated.
Keywords
Pharmaceutical Industry, Mergers and Acquisitions, sanofi-aventis, Synergy Effects, Core Competences, Market Power, Globalisation, Patents, Generics, Innovation Potential, Health Care Systems, Corporate Strategy, Consolidation, Direct to Customer, Management Motives
Frequently Asked Questions
What is the primary focus of this research paper?
The paper examines the drivers and outcomes of mergers and acquisitions in the pharmaceutical sector, focusing specifically on the creation of the sanofi-aventis group as a practical example.
What are the main thematic areas covered in the document?
Key themes include the impact of market globalization, patent expiry, generic competition, healthcare system reforms, and the strategic pursuit of synergy effects by large pharmaceutical companies.
What is the central research question?
The work aims to evaluate why pharmaceutical companies engage in mergers and what the subsequent consequences are for the industry, specifically regarding market competition, price pressure, and corporate innovation.
Which scientific approach is utilized?
The author employs a case study method, analyzing the historical development and strategic rationale behind the sanofi-aventis merger while contrasting it with general industry trends and economic theories.
What topics are discussed in the main part of the work?
The main part details the history of sanofi-aventis, analyzes the reasons for M&As (such as patent expiry and buyer consolidation), explores motives like synergy and market power, and assesses the negative impacts like job cuts and price wars.
Which keywords best characterize this work?
Key terms include pharmaceutical industry, M&A, synergy, core competences, market power, globalization, and patent expiry.
How does the author define the motive of "synergy effects"?
Synergy effects are defined as potential cost reductions and efficiency gains achieved through mass production, streamlining processes, and economies of scope via shared service centers.
What is the significance of the "Monsier Fusion" nickname mentioned in the text?
The nickname refers to Jean-Francois Dehecq, the CEO of sanofi-aventis, and highlights his aggressive strategy of continuous corporate acquisitions, which is discussed as a potential management motive.
- Citation du texte
- Dipl.-Kfm. (FH), MBA Martin Wenderoth (Auteur), 2008, The merger of "sanofi-aventis" as an example for Reasons and Consequences of Mergers and Acquistions in the Pharmaceutical Industry, Munich, GRIN Verlag, https://www.grin.com/document/122117
